Organization | Burroughs Wellcome

Burroughs Wellcome Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: London United Kingdom (1880)

Status: Acquired by Glaxo Wellcome (1995) → now GlaxoSmithKline (2000)

Organization Overview

First Clinical Trial

1985

NCT00209352

First Marketed Drug

1948

bacitracin (polysporin)

First NDA Approval

1948

bacitracin (polysporin)

Last Known Activity

2019

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Burroughs Wellcome

Active Ingredients

Indications

Approved Indications

Epilepsy, Tonic-Clonic

Eye Infections, Bacterial

Lennox Gastaut Syndrome

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Follicular

Lymphoma, Non-Hodgkin

Musculoskeletal Manipulations

Ovarian Neoplasms

Pneumonia

Pneumonia, Pneumocystis

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Rhinitis, Allergic, Seasonal

Seizures

Skin Diseases

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 3)

Hepatitis B (Phase 4)

HIV Infections (Phase 1)

Infections (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Varicella Zoster Virus Infection (Phase 3)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 4

Burroughs Wellcome Report issue

Mergers & Acquisitions

Marketed Drugs (15)

Drugs in Phase 4 Trials (1)

Drugs in Phase 3 Trials (1)

Drugs in Phase 2 Trials (1)

Drugs in Phase 1 Trials (1)

Approved Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Overview